ContraVir, Korn Ferry Make Big Moves After Hours

ContraVir Pharmaceuticals Inc CTRV shares are up 24% after the FDA responded to the company’s IND package and concurred with the company’s proposed plan for further preclinical studies to support the development of CRV431 in NASH.

Korn Ferry KFY shares are down 6% after fourth-quarter adjusted earnings fell in-line with consensus at 88 cents per share. Sales came in at $502.5 million, beating estimates by $3.05 million. First-quarter sales guidance game in below analyst estimates.